Federal enforcement against CBD medical claims in the US is going strong, with the Federal Trade Commission (FTC) recently sending a warning letter to a new company about what it said were prohibited medical claims
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.